Early Detection Initiative for Pancreatic Cancer

NAActive, not recruitingINTERVENTIONAL
Enrollment

8,869

Participants

Timeline

Start Date

October 14, 2021

Primary Completion Date

January 31, 2028

Study Completion Date

January 31, 2028

Conditions
HyperglycemiaDiabetes MellitusPancreas Ductal Adenocarcinoma
Interventions
OTHER

Enriching New-onset Diabetes for Pancreatic Cancer (ENDPAC) score

ENDPAC is a model to risk-stratify patients with new onset diabetes and hyperglycemia for PDAC. Score is calculated using i) age, ii) change, over past year, in body weight and iii) change, over past year, in glucose/HbA1c values obtained from the electronic medical record.

OTHER

Abdominal imaging

Using computerized tomography (CT) scan or magnetic resonance imaging (MRI), if CT scan is contra-indicated, patients with a high ENDPAC score (\>0) are approached for informed consent to participate in the imaging intervention. Imaging (CT scan) is performed at up to two time points, study baseline and approximately 3-9 months following the first imaging study.

Trial Locations (2)

77030

Baylor College of Medicine, Houston

91101

Kaiser Permanente Southern California, Kaiser Permanente Research, Pasadena

All Listed Sponsors
lead

Pancreatic Cancer Action Network

OTHER